Session » Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

Date: Tuesday, November 9, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 1779

A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)

8:30AM-10:30AM: Abstract Number: 1781

A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden

8:30AM-10:30AM: Abstract Number: 1800

Altered Metabolic Profiles in the Transition from Psoriasis to Psoriatic Arthritis: A Longitudinal Analysis

8:30AM-10:30AM: Abstract Number: 1794

Application of Treat to Target and Impact of Sustained Low Disease Activity or Remission on Function in Psoriatic Arthritis Patients

8:30AM-10:30AM: Abstract Number: 1797

Are Smoking and Alcohol Associated with Peripheral Musculoskeletal Involvement in Patients with Spondyloarthritis? Results from the ASAS-PerSpA Study

8:30AM-10:30AM: Abstract Number: 1777

Association of Opioid Use and Opioid-Related Costs with Patient-Reported Outcomes in Patients with Psoriatic Arthritis or Ankylosing Spondylitis

8:30AM-10:30AM: Abstract Number: 1786

Association of the Improvement of Synovitis and Enthesitis with Quality of Life/Patient Reported Outcomes in Patients with PsA Treated with Ixekizumab

8:30AM-10:30AM: Abstract Number: 1774

Blood-based Immune Profiling Combined with Machine Learning Discriminates Psoriatic Arthritis from Psoriasis Patients

8:30AM-10:30AM: Abstract Number: 1784

Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry

8:30AM-10:30AM: Abstract Number: 1773

Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials

8:30AM-10:30AM: Abstract Number: 1782

Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies

8:30AM-10:30AM: Abstract Number: 1796

Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study

8:30AM-10:30AM: Abstract Number: 1799

Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1793

Impact of Gender and Age on Psoriatic Arthritis Patient Profiles at Golimumab Initiation and 12-Month Outcomes

8:30AM-10:30AM: Abstract Number: 1788

Improving Care and Capacity Through Capturing and Recording Patient Reported Outcomes with Digital Solutions in Spondyloarthritis

8:30AM-10:30AM: Abstract Number: 1775

Isolated Axial versus Concomitant Peripheral Disease in Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1783

National Trends in Hospitalizations for Serious Infections in People with Psoriatic Arthritis Using the National Inpatient Sample 2012 – 2017

8:30AM-10:30AM: Abstract Number: 1792

Participation in Psoriatic Arthritis (PART2) – a Cross-sectional Study of Work Impairment in Psoriatic Arthritis Patients in the Netherlands

8:30AM-10:30AM: Abstract Number: 1789

Prediction of Psoriatic Arthritis in Patients with Psoriasis Using DNA Methylation Profiles

8:30AM-10:30AM: Abstract Number: 1785

Prevalence and Incidence of PsA in Germany – a Cohort Study with 65 Million Participants

8:30AM-10:30AM: Abstract Number: 1791

Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry

8:30AM-10:30AM: Abstract Number: 1780

Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1790

Regional Differences in Clinical Characteristics and Treatment of Psoriatic Arthritis with Axial Involvement: Results from the Cross Sectional International ASAS PerSpA Study

8:30AM-10:30AM: Abstract Number: 1776

Stakeholder Outcome Prioritization in the Biologic Abatement and Capturing Kids’ Outcomes and Flare Frequency in Juvenile Spondyloarthritis Trial

8:30AM-10:30AM: Abstract Number: 1778

The Role of Cathepsin G in Joint Destruction in Patients with Psoriatic Arthritis

8:30AM-10:30AM: Abstract Number: 1798

The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?

8:30AM-10:30AM: Abstract Number: 1795

Validation of the Disease Activity Index for Psoriatic Arthritis (DAPSA) with a Quick QuantitativeC-reactive Protein Assay (Q-DAPSA) in Patients with Psoriatic Arthritis (PsA): A Prospective,national, Multicenter Study

8:30AM-10:30AM: Abstract Number: 1787

What Is Peripheral SpondyloArthritis? Identifying Disease Phenotype and Burden: A Post Hoc Analysis of the ASAS-PerSpA International Study

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].